Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. (From -To)
REPORT DATE (DD-MM-YYYY)
01-04-2007
REPORT TYPE
Revised Final
DATES COVERED
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBERUniversity of Florida Gainesville, FL 32610
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTES
ABSTRACTThe goal of this project is to specify how anti-angiogenic approaches can be effectively applied to NF1 tumors. Invivo and in vitro models were used to firmly conclude that Nf1 haploinsufficiency in endothelial cells results inexaggerated proliferation and angiogenesis in response to key pro-angiogenic factors. Results implicate these growthfactor pathways as potential targets for therapeutic agents. In addition, endostatin was found to be a potent inhibitorof Nf1+/-endothelial cell migration in vitro, suggesting endostatin may be an effective antiangiogenic agent forreducing NF1 tumor growth. Two intraneural xenograft models of NF1 peripheral nerve sheath tumors weredeveloped and characterized. Tumor growth and vascularity of NF1 tumor xenografts was quantified by advancedMRI, gadolinium permeability and dynamic contrast enhancement that match results obtained by conventionalhistological measurements. Several methods to deliver endostatin in vivo were tested and several difficulties wereencountered. Finally, cell factories made by alginate-encapsulation of 293 cells transfected with AAV-endostatinwere developed and are being refined to deliver consistent, high-dose systemic levels of endostatin. The effects ofsystemic endostatin on NF1 xenograft tumor growth will be completed in a no-cost extension of this project.
SUBJECT TERMSCancer biology, angiogenesis, xenograft, gene therapy, anti-angiogenic therapy, MRI
INTRODUCTIONNeurofibromatosis type 1 (NF1) is a common genetic disease with a wide variety of features which primarily involve the nervous system and related tissues. NF...